Your Search Results

Percutaneous management of mitral and aortic valve disease

21 May 2026 – From EuroPCR 2026

Delve into the percutaneous management of mitral and aortic valve disease through detailed procedural demonstrations. This session covers valve-in-valve procedures, navigation of potential complications in valve-in-valve TAVI, and mitral valve edge-to-edge repair techniques, supported by real-world case discussions and key learnings.

Pharmacology without borders, from coronary artherostenosis to radial artery

21 May 2026 – From EuroPCR 2026

This session delves into the expansive role of pharmacology in interventional cardiology, addressing topics ranging from coronary atherostenosis to radial artery management. Key discussions include the real-world efficacy and safety of intravenous cangrelor-assisted PCI in chronic coronary syndromes, comparative analysis of intra-arterial verapamil versus placebo for...

Innovations in TAVI: TAVI 2.0

21 May 2026 – From EuroPCR 2026

This session presents cutting-edge advancements in transcatheter aortic valve implantation (TAVI), highlighting the TAVI 2.0 era. It encompasses innovative techniques such as percutaneous and non-fluoroscopic TAVR guided by transthoracic echocardiography (TTE), novel alternative access via the left subscapular approach, and patient-tailored commissural alignment assessed through CT...

Challenging procedures for bifurcation lesions

22 May 2026 – From EuroPCR 2026

Explore a series of challenging cases in coronary bifurcation interventions, highlighting complex decision-making scenarios, pharmaco-invasive strategies guided by IVUS, and tailored techniques for reintervention. Emphasis is placed on imaging-guided PCI and simplifying complex double bifurcation and long lesion treatments to optimize patient outcomes.

Beyond stent: use of DCB in CTO

22 May 2026 – From EuroPCR 2026

This session focuses on the innovative use of drug-coated balloons (DCB) in chronic total occlusion (CTO) interventions. It reviews combined plaque modification techniques, complex multivessel PCI cases involving CTOs, and strategy considerations such as hybrid therapy versus full metal jacket, emphasizing vessel biology preservation during revascularisation.

New insights into pharmacological treatment for STEMI

21 May 2026 – From EuroPCR 2026

This session presents the latest pharmacological advances in the treatment of ST-segment elevation myocardial infarction (STEMI). It covers safety data on ticagrelor monotherapy post-primary PCI, the impact of P2Y12 inhibitor pretreatment, effects of dapagliflozin on myocardial remodeling, and considerations for bleeding risk and vascular preparation strategies...

Is there a rule for DCB in ACS setting?

22 May 2026 – From EuroPCR 2026

This session examines the application of drug-coated balloons (DCB) in the acute coronary syndrome (ACS) setting, comparing outcomes with drug-eluting stents (DES). It discusses the impact of intraluminal thrombus, real-world registry data on DCB-first strategies in STEMI, and multicentre experiences with DCB use in STEMI and...

Updates in tricuspid TEER

21 May 2026 – From EuroPCR 2026

This session offers comprehensive updates on transcatheter edge-to-edge repair (TEER) for tricuspid valve disease. It reviews meta-analyses on outcomes in patients with cardiac implantable electronic device leads, long-term trial results, echocardiographic and clinical outcomes, right ventricular mechanics, risk scoring, and the impact of renal function and...

MASTER-DAPT: “the MASTER of high-bleeding risk trials”

28 Aug 2021

Marco Valgimigli (Lugano, Switzerland) presented the results of the MASTER DAPT trial on Saturday, August 28, in a Hot Line session of the ESC Congress 2021. Luis G. Ortega-Paz provides his PICOT & SWOT analysis of this study.

Author

Luis Ortega-Paz

ESC Congress 2021 - MASTER-DAPT : “the MASTER of high-bleeding risk trials”

On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial

05 Mar 2023

Mirvat Alasnag provides her take on this clinical trial presented by Yundai Chen at the American College of Cardiology Scientific Session (ACC.23/WCC).

Author

Mirvat Alasnag

$On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial$

SMT’s Hydra TAVR Valve demonstrates sustained safety, durability, and hemodynamic performance at 5 Years

19 Nov 2025

TRISCEND II trial: Randomized comparison of transcatheter valve replacement vs. optimal medical therapy for severe tricuspid regurgitation

04 Nov 2024

Alex Sticchi provides his take on the results of the TRISCEND II trial presented by Susheel K. Kodali and Suzanne V. Arnold at TCT 2024 in Washington.

Also watch the interview with Susheel K. Kodali